You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Engineered Pan-Specific Reagents for N-Glycan Detection and Enrichment
SBC: GLYCOSENSORS AND DIAGNOSTICS, LLC Topic: 100PROJECT SUMMARY Glycans play crucial roles in nearly every aspect of biological processes, and their distinct properties make them appealing as disease biomarker targets. However, due to their highly branched and variably linked nature, glycans pose a challenge for detection, purification, and structural analysis. Although advanced analytical techniques and instrumentation have been developed that ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury
SBC: PROTHERA BIOLOGICS, INC. Topic: 105Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel targeted CAR-T multiple myeloma therapy
SBC: Novab, Inc. Topic: 102PROJECT SUMMARY Multiple myeloma (MM), a malignancy of plasma cells (PCs), is responsible for over 12,500 deaths in the US and over 117,000 deaths worldwide annually. Over 91,000 individuals in the US and over 300,000 worldwide currently live with MM. In spite of major therapeutic advances in the past two decades, MM remains incurable and most MM patients succumb to the underlying malignancy. Rece ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A new approach to monitoring glycosylation during glycoprotein production
SBC: GLYCOSENSORS AND DIAGNOSTICS, LLC Topic: 300PROJECT SUMMARY During the production of therapeutic biologicals, glycosylation has been identified as a critical quality attribute (CQA) that must be carefully monitored to ensure that the desired protein stability, immunogenicity, antibody effector function, pharmacological safety and potency, and serum half-life are consistently obtained. Many factors can affect the composition of the glycan ch ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
An assistive-technology based Caregiver Training Program (CTP) to enhance caregiver effectiveness, well-being, and quality of life, which will improve overall care for individuals living with AD/ADRD.
SBC: MAPHABIT INC Topic: RProject Summary Abstract The MapHabit System (MHS) is our neuroscience-based interactive care management platform that utilizes a patented visual mapping system supported by smart devices to improve cognition and reinforce routine habits in individuals living with AD/ADRD. The MHS approach relies on the discovery that certain regions of the brain that underlie habit and procedural learning are spa ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis
SBC: PROTHERA BIOLOGICS, INC. Topic: NICHDNecrotizing enterocolitis (NEC) is a devastating acute inflammatory condition of the gastrointestinal tract resulting in intestinal necrosis, systemic sepsis and multi-system organ failure found mostly in infants born prematurely. Despite modern medical advances in the past decade, the etiology remains elusive and morbidity and mortality are still unacceptably high. It has been concluded that the ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Improving physical function and quality of life in older adults with prediabetes utilizing interactive small-group resistance training through video conference technology
SBC: IMPACTIV, INC. Topic: NIAVivo is a virtual small group exercise program designed for adults 55 and over that is unique in the increasingly popular digital fitness market. Vivo offers 3 key market differentiators: 1) a personalized and individualized live training experience with feedback from a certified trainer, 2) a community of older adult exercisers which enhances motivation and social support, and increase accountabi ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of Monoclonal Antibodies for the Study of Mycobacterium tuberculosis (Mtb) in the Guinea Pig
SBC: GLYCOSCIENTIFIC, L.L.C. Topic: 118GlycoScientific proposes to generate antibodies specific for six inflammatory cytokines to elucidate and correlate immunological markers of tuberculosis (TB) transmission and disease development in the guinea pig. Once the antibodies are produced, the Offeror will use them to evaluate the cytokines in TB infected and non-infected guinea pigs. The production of these crucial immunological reagents ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Commercial Readiness for Direct-to-Digital Pathology
SBC: APPLIKATE TECHNOLOGIES, INC. Topic: NCIAbstract Project Summary Applikate Technologies has developed Clearing Histology with Multiphoton Microscopy (CHiMP), a novel tissue processing and imaging platform that provides direct-to-digital images from intact pathology tissue specimens, such as biopsies, without the need for wax embedding, slicing, or scanning of slides. The application of this technology to cancer diagnosis will reduce err ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
F plus G RSV VLP Vaccine for Improved Safety and Efficacy
SBC: RAZI PHARMA LLC Topic: NIAIDProject Summary Respiratory syncytial virus (RSV) is a leading cause of serious lower respiratory tract disease in infants and young children worldwide. Since infection induces only partial protection, it causes repeat infection and disease throughout life. Though a high priority for vaccine development no vaccine is yet available. The lack of success in developing a vaccine suggests novel strateg ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health